Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy

Cancer Biology and Therapy

Volumn 15, Issue 6, 2014, Pages 699-706

  Jacobs, Corbin D ^a   Chun, Stephen G ^a   Yan, Jingsheng ^b   Xie, Xian Jin ^b   Pistenmaa, David A ^a   Hannan, Raquibul ^a   Lotan, Yair ^a   Roehrborn, Claus G ^a   Choe, Kevin S ^a   Kim, D W Nathan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anticoagulant; Aspirin; Prostate cancer; Radiotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; ANTICOAGULANT AGENT; CLOPIDOGREL; PROSTATE SPECIFIC ANTIGEN; WARFARIN; TICLOPIDINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; FREEDOM FROM BIOCHEMICAL FAILURE; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATE CANCER; RADIATION INJURY; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHEMORADIOTHERAPY; DRUG SCREENING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; CHEMORADIOTHERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; TICLOPIDINE; TREATMENT OUTCOME; WARFARIN;

EID: 84901721331     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28554     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol 2013; 23:331-6; PMID:23619582; http://dx.doi.org/10.1097/MOU. 0b013e328361d48e
3. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010; 8:145; PMID:20141674
4. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26:2497-504; PMID:18413638; http://dx.doi.org/10.1200/JCO. 2007.14.9021
5. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al.; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360:2516-27; PMID:19516032; http://dx.doi.org/10.1056/NEJMoa0810095
6. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11:1066-73; PMID:20933466; http://dx.doi.org/10.1016/S1470-2045(10)70223-0
7. Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys 2013; 86:721-8; PMID:23664325; http://dx.doi.org/10.1016/ j.ijrobp.2013.03.028
8. Choe KS, Liauw SL. Effects of aspirin on cancer initiation and progression. Expert Rev Anticancer Ther 2013; 13:115-7; PMID:23406550; http://dx.doi.org/10.1586/era.12.166
9. Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer 2010; 116:1820-6; PMID:20143436; http://dx.doi.org/10.1002/cncr.24890
10. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012; 30:3540-4; PMID:22927523; http://dx.doi.org/10. 1200/JCO.2011.41.0308
11. Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, et al.; PROSTQA Consortium Study Group. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys 2013; 86:546-53; PMID:23561651; http://dx.doi.org/10. 1016/j.ijrobp.2013.01.036
12. Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys 2010; 76:755-60; PMID:19464123; http://dx.doi.org/10.1016/j.ijrobp.2009.02.026
13. Moon CM, Kwon JH, Kim JS, et al. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int J Cancer 2014; 134:519-29; PMID:23852449; http://dx.doi.org/doi: 10.1002/ijc.2838
14. Wang L, Zhao Y, Liu Y, Akiyama K, Chen C, Qu C, Jin Y, Shi S. IFN-γ and TNF-α synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFê B signaling. Stem Cells 2013; 31:1383-95; PMID:23553791; http://dx.doi.org/10.1002/stem.1388
15. Khor L-Y, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007; 8:912-20; PMID:17881290; http://dx.doi.org/10.1016/S1470-2045(07) 70280-2
16. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006; 12:2172-7; PMID:16609031; http://dx.doi.org/10.1158/1078-0432.CCR-05- 2067
17. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24:2723-8; PMID:16782912; http://dx.doi.org/10.1200/JCO.2005.03.7804
18. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004; 93:275-8; PMID:14764122; http://dx.doi.org/10.1111/j.1464-410X.2004.04601.x
19. Saha D, Pyo H, Choy H. COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. Am J Clin Oncol 2003; 26:S70-4; PMID:12902860; http://dx.doi.org/10.1097/01.COC.0000074161.92815.93
20. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9:259-67; PMID:22473097; http://dx.doi.org/10.1038/ nrclinonc.2011.199
21. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer 2009; 115:4470-6; PMID:19637339; http://dx.doi.org/10.1002/cncr.24526
22. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer 2006; 107:2392-400; PMID:17041884; http://dx.doi.org/10.1002/cncr.22261
23. Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). BJU Int 2012; 110:973-9; PMID:22954029; http://dx.doi.org/10.1111/j.1464-410X.2012.11470.x
24. rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965-74; PMID:16798415; http://dx.doi.org/10. 1016/j.ijrobp.2006.04.029